BioMark Diagnostics Inc. (BMKDF) Research

BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer. These solutions are designed to aid in the identification of the disease, its ongoing monitoring, and the assessment of initial therapeutic interventions. The company has a research partnership with the Icahn School of Medicine, under which they conduct clinical studies concentrating on the early detection of lung cancer. Established in 2014, BioMark Diagnostics Inc. has its main office in Richmond, Canada, and functions as a subsidiary of Biomark Technologies Inc.

Market snapshot

Symbol
BMKDF
Price
$0.40
Day change
0.00%
Market cap
$56.7M
P/E ratio
-33.39x
52-week range
0.2034-0.5044
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • Cordlife Group Limited (CLIFF)
  • Celyad Oncology S.A. (CLYYF)
  • Fluent Corp. (CNTMF)
  • DIAGNOS Inc. (DGNOF)
  • Evolva Holding S.A. (ELVAF)
  • ImpediMed Limited (IPDQF)
  • Izotropic Corporation (IZOZF)
  • Marpai, Inc. (MRAI)

Open BioMark Diagnostics Inc. (BMKDF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.